Skip to main content
. Author manuscript; available in PMC: 2018 Aug 16.
Published in final edited form as: J Abnorm Psychol. 2013 Aug;122(3):733–744. doi: 10.1037/a0033956

Table 1.

Demographic and Clinical Information

SZP Group (n = 48) Control Group (n = 28)

Sex (% male) 83.3 92.8

Race/ethnicity (% Caucasian) 58.3 96.4

Age (years) 40.78 (11.76) 43.62 (9.49)
Education (years) 11.57 (1.76) 16.07 (1.83)

Parental Education (years) 12.51 (2.12) 12.55 (2.18)

Mini-Mental State Examination (out of 30) 26.21 (2.6) 29.23 (.81)

Medication
 Chlorpromazine equivalents 335.36 (355.8)
 Range 0 – 1906.82
% taking antipsychotics 97.91
 % taking mood stabilizers 43.75
 % taking antidepressants 56.25
 % taking anticholinergics 18.75
 % taking anxiolytics 29.17

SAPS Global Ratings M (SD)

 Hallucinations 1.88 (1.89)

 Delusions 2.87 (1.41)

 Positive Formal Thought Disorder 1.72 (1.5)

Physical Anhedonia Scale 16.92 (7.71) 11.5 (6.91)

Social Anhedonia Scale 15.78 (6.73) 10.36 (7.69)

Note: SAPS - Scale for the Assessment of Positive Symptoms